DRAFT

Amendments to the Claims

1.	(Cancelled)
2.	(Currently amended) The method of claim 70 9, wherein the cardiac muscle tissue is ischemic cardiac muscle tissue.
3-4	(Cancelled)
5.	(Currently amended) The method of claim 70 9, wherein the cardiac muscle tissue is damaged cardiac muscle tissue.
6.	(Cancelled)
7.	(Previously amended) The method of claim 5, wherein the damaged cardiac muscle tissue is an artificially created site.
8.	(Cancelled)
9.	(Currently amended) The A method of claim 8 forming new blood vessels in cardiac muscle tissue in a subject, wherein the mammal subject is a human, which comprises: a) isolating autologous bone marrow-mononuclear cells from the human;
	 and transplanting locally into the cardiac muscle tissue an effective amount

of the autologous bone-marrow mononuclear cells, resulting in

formation of new blood vessels in the cardiac muscle tissue.

DRAFT

- 11. (Currently amended) The method of claim 70 9, wherein the new blood vessels comprise collateral vessels.
- 12. (Cancelled)
- 13. (Currently amended) The method of claim 71 22, wherein the new blood vessels comprise capillaries.
- 14. (Currently amended) The method of claim 71 22, wherein the new blood vessels comprise collateral blood vessels.
- 15. (Currently amended) The method of claim 71 22, wherein the cardiac muscle tissue is ischemic cardiac muscle tissue.
- 16-17 (Cancelled)
- 18. (Currently amended) The method of claim 71 22, wherein the cardiac muscle tissue is damaged cardiac muscle tissue.
- 19. (Cancelled)
- 20. (Previously amended) The method of claim 18, wherein the damaged cardiac muscle tissue is an artificially created site.
- 21. (Cancelled)
- 22. (Currently amended) A The method of claim 21, of increasing blood flow to cardiac muscle tissue in a subject, wherein the mammal subject is a human, which comprises:
 - a) isolating autologous bone-marrow mononuclear cells from the human;

DRAFT

and

- b) transplanting locally into the cardiac muscle tissue an effective amount of the autologous bone-marrow mononuclear cells so as to result in formation of new blood vessels in the cardiac muscle tissue, thereby increasing the blood flow to the cardiac muscle tissue in the human.
- 23. (Cancelled)
- 24. (Currently amended) The method of claim 72 31, wherein the diseased cardiac muscle tissue is ischemic cardiac muscle tissue.
- 25-27 (Cancelled)
- 28. (Currently amended) The method of claim 72 31, wherein the new blood vessels comprise capillaries.
- 29. (Currently amended) The method of claim 72 31, wherein the new blood vessels comprise collateral blood vessels.
- 30. (Cancelled)
- 31. A The method of claim 30 treating diseased cardiac muscle tissue in a subject, wherein the mammal subject is a human, which comprises:
 - a) isolating autologous bone-marrow mononuclear cells from the human; and
 - b) transplanting locally into the diseased cardiac muscle tissue an effective amount of the autologous bone-marrow mononuclear cells so as to result in formation of new blood vessels, thereby treating the diseased cardiac muscle tissue in the human.

RAFT

- 32. (Cancelled)
- 33. (Currently amended) The method of claim 73 38, wherein the diseased cardiac muscle tissue is ischemic cardiac muscle tissue.
- 34-36 (Cancelled)
- 37. (Cancelled)
- 38. (Currently amended) A The method of claim 37 increasing angiogenesis in diseased cardiac muscle tissue in a subject, wherein the mammal subject is a human, which comprises:
 - a) isolating autologous bone-marrow mononuclear cells from the human;
 and
 - transplanting locally into the diseased cardiac muscle tissue an effective amount of the autologous bone-marrow mononuclear cells, thereby increasing angiogenesis in the diseased cardiac muscle tissue in the human.
- 39. (Cancelled)
- 40. (Currently amended) The method of claim 39 43, wherein the new blood vessels comprise capillaries.
- 41. (Currently amended) The method of claim 39 43, wherein the new blood vessels comprise collateral blood vessels.
- 42. (Cancelled)
- 43. (Currently amended) A The method of claim 42 treating heart failure in a mammal, wherein

JRAFT

the mammal subject is a human, which comprises:

- a) isolating autologous bone-marrow mononuclear cells from the human; and
- b) transplanting locally into the heart an effective amount of the autologous bone-marrow mononuclear cells so as to result in formation of new blood vessels, thereby treating heart failure in the human.

44-69 (Cancelled)

- 70. (Cancelled)
- 71. (Cancelled)
- 72. (Cancelled)
- 73. (Cancelled)